|
|
|
| The sensitivity of the ketogenic metabolic therapy in cancer depends on the expression of ketolytic key enzymes |
| ZHANG Jie, CONG Ming-hua, GAO Yun |
|
|
|
|
Abstract Objective Although ketogenic diet (KD) has been studied its certain anti-tumor effect by basic research and clinical trials, the specific molecular targets or indications which verify its anti-tumor activity are lack. In this study, we examined the expression of different ketolytic key enzymes to identify the sensitivity of KD in tumor cells. MethodsExpression of genes encoding 3-hydroxybutyrate dehydrogenase 1 (BDH1) and succinyl-CoA: 3-oxoacid CoA transferase 1 (OXCT1) have been determined in 33 human cancer cell lines by quantitative RT-PCR. HeLa cell and pan-1 cell were selected with high expressing and low expressing two enzymes respectively. Proliferation of HeLa and PANC-1 cells was determined by using a hand-held automatic cell counter after cultured in low glucose medium with or without DL-β-Hydroxybutyric acid sodium salt (βHB). BDH1 and OXCT1 were knocked down in HeLa cells by lentivirus-mediated RNA interference and established HeLa and PANC-1 cell xenograft tumors models in BALB/C nude mice to identify the sensitivity of KD in anti-tumor therapy. Results Compared to control group, proliferation of HeLa and PANC-1 cells in low glucose (LG) was significantly inhibited. Howevere, proliferation of HeLa cells was significantly increased, while added βHB into LG group, but there was no significant effect on proliferation of PANC-1 cells. Animal experiments demonstrated that KD inhibited growth of PANC-1 cell xenograft tumors dramatically, but no effect on the growth of HeLa xenograft tumor. Down-regulation of both BDH1 and OXCT1 in HeLa cells rendered their sensitivity to KD in vitro and in vivo. ConclusionsTumors with low expression of ketolytic enzymes which are not obviously induced gene expression are sensitive to ketogenic metabolic therapy.
|
|
|
|
|
|
| [1] |
1HOU Yi-ran，1LI Bao-li， 2XING Jin-liang， 3LI Ji-bin. Metabolic reprogramming in liver cancer and its potential clinical implications[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(3): 295-300. |
| [2] |
1YANG Zhen-peng， 1DENG Li， 1RAO Ben-qiang， 2PAN Guo-feng， 3JIN Shuai. Molecular communication and mitochondrial metabolism[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(3): 277-282. |
| [3] |
SUN Xue-hua， ZHOU Fu-xiang. Current problems and thinkings on the cancer metabolic modulation therapy[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(3): 287-294. |
| [4] |
1，4 SONG Meng-meng，2CHEN Zhe-wen，3 LI Ye，1，4 SONG Chun-hua，5SHI Han-ping，6MIAO Ming-yong. Advances in anti-tumor effect of mannose[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(3): 283-286. |
| [5] |
1YAO Ke-qing， 1WANG Su， 1CHEN Shuang， 1SUN Yan-teng， 1LIU Qing-yang， 1CHEN Tao，1LIU Xue-hui， 2CONG Ming-hua. Application of individualized nutrition diagnosis and intervention in patients with advanced cancer[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(3): 305-309. |
| [6] |
1，2ZHU Ming-xing， 1WU Chang-peng， 3YIN Liang-yu，1LU Zong-liang， 1LI Na，1LIU Jie， 1GUO Jing， 1XU Hong-xia. L-carnitine improves skeletal muscle cell atrophy of cancer cachexia by regulating lipid metabolism[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(3): 320-325. |
|
|
|
|
